We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+15.42%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$11.9M
Cap. Flow
-$17.7M
Cap. Flow %
-5.47%
Top 10 Hldgs %
51.2%
Holding
69
New
3
Increased
9
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.99M
2
PTCT icon
PTC Therapeutics
PTCT
+$5.11M
3
ILMN icon
Illumina
ILMN
+$4.58M
4
TVTX icon
Travere Therapeutics
TVTX
+$4.09M
5
AZN icon
AstraZeneca
AZN
+$4.08M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.6M
3
BIIB icon
Biogen
BIIB
+$6.81M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$5.25M
5
INCY icon
Incyte
INCY
+$4.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCM icon
51
HUTCHMED
HCM
$2.16B
$1M 0.31%
68,000
– –
BEAM icon
52
Beam Therapeutics
BEAM
$3.15B
$919K 0.28%
23,500
– –
NTLA icon
53
Intellia Therapeutics
NTLA
$1.84B
$837K 0.26%
24,000
– –
ALBO
54
DELISTED
Albireo Pharma Inc
ALBO
$820K 0.25%
38,000
+21,907
+136% +$463K
INSM icon
55
Insmed
INSM
$26.5B
$800K 0.25%
40,100
– –
IRWD icon
56
Ironwood Pharmaceuticals
IRWD
$701M
$743K 0.23%
60,000
– –
BCRX icon
57
BioCryst Pharmaceuticals
BCRX
$2.52B
$654K 0.2%
57,000
– –
ARVN icon
58
Arvinas
ARVN
$604M
$581K 0.18%
17,000
– –
FATE icon
59
Fate Therapeutics
FATE
$304M
$464K 0.14%
46,000
-75,000
-62% -$1.41M
IOVA icon
60
Iovance Biotherapeutics
IOVA
$3.74B
$357K 0.11%
56,000
– –
ALLO icon
61
Allogene Therapeutics
ALLO
$722M
$314K 0.1%
50,000
– –
RLMD icon
62
Relmada Therapeutics
RLMD
$482M
$34.9K 0.01%
10,000
– –
AXSM icon
63
Axsome Therapeutics
AXSM
$10.8B
– –
-14,000
Closed -$625K
LKFT
64
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
– –
-123,300
Closed -$5.25M
KALV
65
DELISTED
KalVista Pharmaceuticals
KALV
– –
-316,133
Closed -$4.59M
MDGL icon
66
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-5,350
Closed -$348K
NBIX icon
67
Neurocrine Biosciences
NBIX
$15.8B
– –
-30,000
Closed -$3.19M
VTRS icon
68
Viatris
VTRS
$19.4B
– –
-364,000
Closed -$3.1M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2022 Portfolio in Review

As of Q4 2022, International Biotechnology Trust held 69 positions worth $324M, up 3.8% from $312M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

International Biotechnology Trust withdrew a net $17.7M in Q4 2022, closing 6 positions and reducing 7 holdings. Its most notable exit was Lakefront Biotherapeutics American Depositary Shares, an estimated $5.25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, International Biotechnology Trust opened a new position in AstraZeneca worth $4.41M.

  • International Biotechnology Trust's largest Q4 2022 buy was AstraZeneca: 32,500 shares worth $4.41M.
  • International Biotechnology Trust added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $6.99M increase.
  • International Biotechnology Trust's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $12M.
  • International Biotechnology Trust fully exited Lakefront Biotherapeutics American Depositary Shares in Q4 2022, selling an estimated $5.25M.
  • International Biotechnology Trust's ten largest holdings make up 51% of its $324M portfolio in Q4 2022.
  • International Biotechnology Trust opened 3 new positions and closed 6 in Q4 2022.
  • International Biotechnology Trust's portfolio value rose 3.8% quarter-over-quarter to $324M.

Based on International Biotechnology Trust's 13F filing for Q4 2022, filed 1 Feb 2023.